Boehringer's Spiriva Respimat improves lung function in children with asthma, study shows

6 September 2016

Boehringer Ingelheim’s Spiriva (tiotropium) Respimat improved lung function in children with asthma aged from six to 17 years when added to maintenance therapy compared to placebo in a Phase III trial and additional pooled data.

The privately-owned German company also announced that the treatment had been well-tolerated as it presented the research results at the European Respiratory Society International Congress (ERS).

In the CanoTinA-asthma trial, tiotropium Respimat was investigated as an add-on therapy for children who were already taking an inhaled corticosteroid (ICS) or an ICS combined with other maintenance therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK